Flor de Maria Munoz
Pediatric Infectious Diseases · Houston, TXNPI 1689754095
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $175,516 of the $268,070 with a category attached, or 65.5%. 13 manufacturers reported payments, led by Sanofi Pasteur Inc. at 27.8% of the total. 2025 is the largest year on record at $106,654, 5.3 times the $20,121 reported in 2019. Among pediatric infectious diseases clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 177 payments — averaging $1514.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi Pasteur Inc.$74K
- Merck$61K
- Pfizer$45K
- Modernatx, Inc.$39K
- Sanofi US Services Inc.$23K
- Astrazeneca UK Limited$6K
- plus $21K from 7 others
Across 163 payments — averaging $56,871 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$8.8M
- Gilead$399K
- Merck$29K
- Biocryst Pharmaceuticals, Inc.$24K
- Modernatx, Inc.$22K
- Sanofi Pasteur Inc.$14K
- plus $5K from 1 others
What the payments were for
- Consulting fees$175,51665%
- Speaking & faculty fees$55,44221%
- Travel & lodging$34,93813%
- Food & beverage$2,1751%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi Pasteur Inc. | 43 | $74,416 |
| Merck | 45 | $60,748 |
| Pfizer | 15 | $45,392 |
| Modernatx, Inc. | 31 | $38,571 |
| Sanofi US Services Inc. | 2 | $22,600 |
| Astrazeneca UK Limited | 9 | $5,771 |
| GSK | 13 | $5,621 |
| Dynavax Technologies Corporation | 7 | $5,500 |
| AstraZeneca | 5 | $4,342 |
| Seqirus USA Inc | 2 | $4,216 |
| Novavax Inc | 2 | $832 |
| Astellas Pharma US Inc | 2 | $47 |
| Lilly USA, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENFLONSIA$22,490
- Moderna Covid-19 Vaccine$20,390
- NO PRODUCT DISCUSSED$7,518
- FLUZONE QUADRIVALENT$6,604
- ADACEL$5,237
- FLUCELVAX QUADRIVALENT (MULTI-DOSE VIAL)$4,216
- Heplisav-B$3,500
- FLUZONE QUADRIVALENT NORTHERN HEMISPHERE$3,290
- FLUMIST QUADRIVALENT$1,600
- NOVAVAX COVID-19 VACCINE, ADJUVANTED$810
- EVUSHELD$483
How this compares
$268,070 in reported general payments places this provider in the 95th percentile of 66 pediatric infectious diseases providers in Texas.
Other pediatric infectious diseases in Houston
- Rene AmayaHouston$43K
- Denver NilesHouston$41K
- Micah BhattiHouston$31K
- Carol BakerHouston$30K
- Gloria HeresiHouston$22K
- Gail DemmlerHouston$5K
- Jeffrey StarkeHouston$4K
- Mark KlineHouston$2K
- Norma PerezHouston$1K
- Liset Olarte CarhuazHouston$892
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.